
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
During the first quarter of 2025, pharmaceutical companies have taken charge to strengthen their biosimilar portfolios, announcing new deals and partnerships that are sure to provide patients across the immunology and oncology fields greater access to life …